Automated Cell Therapy Manufacturing Platforms Market
完整報告名稱與涵蓋範圍
Automated Cell Therapy Manufacturing Platforms Market Size, Share & Trends Analysis Report, By Platform Type (Closed Automated End-to-End Manufacturing Systems, Automated Unit Operation Instruments (Selection, Activation, Expansion, Formulation), Robotic and Modular Manufacturing Cells, Process Control and Digital Manufacturing Software), By Therapy Type (Autologous CAR-T and TCR-T, Allogeneic Cell Therapies, iPSC-Derived and Other Cell Products), By Manufacturing Model (Centralized Manufacturing, Decentralized and Point-of-Care Manufacturing), By End User, By Region, and Segment Forecasts, 2026-2035
報告摘要
The automated cell therapy manufacturing platforms market covers closed end-to-end systems, automated unit-operation instruments, robotic manufacturing cells and the digital control software used to produce autologous and allogeneic cell therapies with minimal manual intervention, for centralised and decentralised manufacturing models. Consumables are included where sold as platform-specific kits; contract manufacturing services and conventional open-process laboratory equipment are excluded.
Manual, cleanroom-intensive manufacturing has limited CAR-T access and kept cost of goods high, so developers and manufacturers are adopting platforms that integrate cell selection, activation, transduction, expansion and formulation in closed cassettes controlled by software, cutting labour, footprint and contamination risk. Fully robotic factories that run many patient batches in parallel, modular systems designed for hospital-based point-of-care production and cloud-connected process control that supports comparability across sites are the leading design directions. Regulatory acceptance of decentralised manufacturing, comparability data for platform transfers and the shift to allogeneic and in vivo therapies will shape how much capacity migrates to automated systems.
North America and Europe lead deployment, with Japan, China and South Korea adopting closed platforms for domestic products. Competition involves cell processing instrument leaders, bioprocess groups, robotics start-ups and cell therapy companies commercialising internally developed platforms.
The InsightAce study supplies US$ forecasts for all platform type, therapy type, manufacturing model and end user and regional segments over 2026-2035, segment-level trend analysis, competitive landscape assessment and profiling of the leading companies.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Automated Cell Therapy Manufacturing Platforms Market Snapshot
Chapter 4. Global Automated Cell Therapy Manufacturing Platforms Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By Platform Type Estimates & Trend Analysis
5.1. Platform Type & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Platform Type:
5.2.1. Closed Automated End-to-End Manufacturing Systems
5.2.2. Automated Unit Operation Instruments (Selection, Activation, Expansion, Formulation)
5.2.3. Robotic and Modular Manufacturing Cells
5.2.4. Process Control and Digital Manufacturing Software
Chapter 6. Market Segmentation 2: By Therapy Type Estimates & Trend Analysis
6.1. Therapy Type & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Therapy Type:
6.2.1. Autologous CAR-T and TCR-T
6.2.2. Allogeneic Cell Therapies
6.2.3. iPSC-Derived and Other Cell Products
Chapter 7. Market Segmentation 3: By Manufacturing Model Estimates & Trend Analysis
7.1. Manufacturing Model & Market Share, 2026 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Manufacturing Model:
7.2.1. Centralized Manufacturing
7.2.2. Decentralized and Point-of-Care Manufacturing
Chapter 8. Market Segmentation 4: By End User Estimates & Trend Analysis
8.1. End User & Market Share, 2026 & 2035
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by End User:
8.2.1. Cell Therapy Developers
8.2.2. CDMOs
8.2.3. Hospitals and Academic Manufacturing Centers
Chapter 9. Automated Cell Therapy Manufacturing Platforms Market: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. United States
9.1.2. Canada
9.2. Europe
9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. South Korea
9.3.5. Australia
9.3.6. Southeast Asia
9.3.7. Rest of Asia Pacific
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Middle East & Africa
9.5.1. GCC Countries
9.5.2. South Africa
9.5.3. Rest of Middle East & Africa
Chapter 10. Competitive Landscape
10.1. Company Market Positioning Analysis
10.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 11. Company Profiles
11.1. Miltenyi Biotec B.V. & Co. KG
11.2. Lonza Group AG (Cocoon)
11.3. Cellares, Inc.
11.4. Thermo Fisher Scientific Inc.
11.5. Cytiva (Danaher)
11.6. Ori Biotech Ltd.
11.7. Multiply Labs, Inc.
11.8. Sartorius AG
11.9. Terumo Blood and Cell Technologies
11.10. Fresenius Kabi AG (Cell Therapy)
11.11. Cellular Origins
11.12. Kite Pharma (Gilead Sciences, Inc.)
11.13. MaxCyte, Inc.
11.14. Xcellbio
11.15. ScaleReady
圖表清單 List of Tables & Figures
Table 1. Global Automated Cell Therapy Manufacturing Platforms Market Revenue Forecast by Platform Type, 2026-2035 (US$ Mn)
Figure 1. Global Automated Cell Therapy Manufacturing Platforms Market Segmentation Overview
Table 2. Global Automated Cell Therapy Manufacturing Platforms Market Revenue Forecast by Therapy Type, 2026-2035 (US$ Mn)
Figure 2. Global Automated Cell Therapy Manufacturing Platforms Market Share by Platform Type, 2026 & 2035
Table 3. Global Automated Cell Therapy Manufacturing Platforms Market Revenue Forecast by Manufacturing Model, 2026-2035 (US$ Mn)
Figure 3. Manual Versus Automated Closed Manufacturing: Labour, Footprint and Cost of Goods Comparison
Table 4. Global Automated Cell Therapy Manufacturing Platforms Market Revenue Forecast by End User, 2026-2035 (US$ Mn)
Figure 4. Global Automated Cell Therapy Manufacturing Platforms Market Share by Therapy Type, 2026 & 2035
Table 5. North America Automated Cell Therapy Manufacturing Platforms Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 5. Centralized, Decentralized and Robotic Factory Models for Cell Therapy Production
Table 6. Europe Automated Cell Therapy Manufacturing Platforms Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Asia Pacific Automated Cell Therapy Manufacturing Platforms Growth Opportunity Analysis
Table 7. Asia Pacific Automated Cell Therapy Manufacturing Platforms Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 7. Regulatory Pathways for Point-of-Care and Distributed Cell Therapy Manufacturing
Table 8. Latin America Automated Cell Therapy Manufacturing Platforms Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 8. Competitive Positioning of Key Automated Cell Therapy Manufacturing Platforms Market Participants
Table 9. Middle East & Africa Automated Cell Therapy Manufacturing Platforms Market Revenue by Country, 2026-2035 (US$ Mn)
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們